IP Library Granted Patent US 12,440,378
Granted Patent B1
US 12,440,378 · App. 19/053,243 · Granted Oct 14, 2025

Devices and systems for cutting, loading, and delivering biologic intraocular implants for increased aqueous outflow and lowering of intraocular pressure

Inventors: Sean Buxton (Harrison, NY); Roderick H. Beaulieu (Harrison, NY); Tsontcho Ianchulev (Harrison, NY); Daniel Nelsen (Harrison, NY); David Robson (Harrison, NY); Joshua Williams (Harrison, NY)
Assignee: Iantrek, Inc.
A61F9/00781A61F9/0017
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,440,378
App. No.
19/053,243
Granted
Oct 14, 2025
Kind
B1
Abstract

A system for treating an eye comprising a tissue stored within a lumen of an elongated cannula, the tissue comprises scleral, amniotic membrane, or acellular biomatrix tissue and having an elongated form factor. Related devices, systems, and methods are provided.

Claims (25)

1. A method of treating glaucoma of an eye comprising:

inserting a first implant in a treatment site in an eye, wherein the implant comprises dehydrated, biologically-derived tissue having a first size;

opening a space within the treatment site with the implant due to the dehydrated, biologically-derived tissue of the implant rehydrating in the eye and expanding from the first size to a second size; and

inserting a second implant near the treatment site of the first implant,

wherein the first implant and the second implant are both formed and cut of dehydrated, biologically-derived tissue, wherein the biologically-derived tissue of the first implant is the same as or different from the biologically-derived tissue of the second implant,

wherein the second implant creates a scaffold with the first implant and a reservoir within a target site between the first implant and the second implant, and

wherein the treatment site is between internal eye tissue layers, and wherein opening the space within the treatment site increases outflow of aqueous from an anterior chamber of the eye through the treatment site between the internal eye tissue layers.

2. The method of claim 1 , wherein the dehydrated, biologically-derived tissue is cornea, sclera, or amniotic membrane.

3. The method of claim 1 , further comprising inserting the first implant into the treatment site ab externo via a scleral flap.

4. The method of claim 1 , further comprising inserting the first implant into the treatment site ab interno.

5. The method of claim 4 , wherein inserting the first implant ab interno comprises advancing a delivery cannula through a cornea of the eye and advancing the delivery cannula towards the treatment site, the first implant having the first size contained within a lumen of the delivery cannula for deploying the first implant in the treatment site.

6. The method of claim 1 , wherein the first size of the first implant comprises a width of 400-800 microns.

7. The method of claim 1 , wherein the second size of the first implant following rehydration is at least 50% up to about 200% greater than the first size of the first implant.

8. The method of claim 1 , wherein the second size of the first implant is at least 1.2× up to about 3× the first size of the first implant.

9. The method of claim 1 , wherein the first implant has a dehydrated maximum thickness of about 600 microns and a hydrated maximum thickness of about 1000 microns.

10. The method of claim 1 , wherein the dehydrated, biologically-derived tissue is dehydrated using ethyl alcohol or by lyophilizing.

11. The method of claim 1 , wherein the treatment site in the eye comprises a suprachoroidal space, a supraciliary space, a Schlemm's canal, or an anterior chamber.

12. The method of claim 1 , wherein the first implant deployed in the treatment site provides aqueous communication between an anterior chamber of the eye and at least one of a supraciliary space, a suprachoroidal space, a Schlemm's Canal, and a sub-conjunctival space.

13. The method of claim 1 , wherein the treatment site includes a sub-conjunctival space of the eye and the first implant extends trans-sclerally from a sub-scleral location to a supra-scleral location.

14. The method of claim 1 , wherein the first implant provides sub-scleral, trans-scleral, or supra-scleral occlusion, stenting, and/or tissue reinforcement.

15. The method of claim 1 , further comprising compressing the first implant into a plug prior to deploying in the treatment site.

16. The method of claim 15 , further comprising stenting the treatment site with the plug.

17. The method of claim 15 , further comprising occluding the treatment site with the plug, the treatment site being a wall rupture or over-filtering bleb.

18. The method of claim 1 , wherein a distance between the first implant and the second implant is about 0.5 mm-2.0 mm around a circumference of the eye.

19. The method of claim 18 , wherein the first implant and the second implant are positioned about 5 degrees to about 20 degrees apart on a 12 mm diameter circle of the eye.

Assignments (2)
SECURITY INTEREST Recorded Apr 15, 2026
From: IANTREK, INC.
To: TRINITY CAPITAL INC., AS COLLATERAL AGENT
Reel/Frame 075423/0518 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2025
From: BUXTON, SEAN; BEAULIEU, RODERICK H.; IANCHULEV, TSONTCHO; NELSEN, DANIEL; ROBSON, DAVID; WILLIAMS, JOSHUA
To: IANTREK, INC.
Reel/Frame 071098/0384 →
Continuity (4)
Continuation 19100424
Provisional Application 63584804 · Sep 22, 2023
Provisional Application 63488920 · Mar 7, 2023
Provisional Application 63427552 · Nov 23, 2022
References Cited (130)
US 1345882A · Repass · 1920 [cited by applicant]
US 4154239A · Turley · 1979 [cited by applicant]
US 4288066A · Treace · 1981 [cited by applicant]
US 5300079A · Niezink et al. · 1994 [cited by applicant]
US 5342370A · Simon et al. · 1994 [cited by applicant]
US 5662661A · Boudjema · 1997 [cited by applicant]
US 5702441A · Zhou · 1997 [cited by applicant]
US 5868697A · Richter et al. · 1999 [cited by applicant]
US 5868728A · Giungo et al. · 1999 [cited by applicant]
US 5941250A · Aramant et al. · 1999 [cited by applicant]
US 6036678A · Giungo · 2000 [cited by applicant]
US 6205177B1 · Girod et al. · 2001 [cited by applicant]
US 7207965B2 · Simon · 2007 [cited by applicant]
US 7291125B2 · Coroneo · 2007 [cited by applicant]
US 7815592B2 · Coroneo · 2010 [cited by applicant]
US 7850638B2 · Theodore Coroneo · 2010 [cited by applicant]
US 7909789B2 · Badawi et al. · 2011 [cited by applicant]
US 8128588B2 · Coroneo · 2012 [cited by applicant]
US 8167939B2 · Silvestrini et al. · 2012 [cited by applicant]
US 8337393B2 · Silverstrini et al. · 2012 [cited by applicant]
US 8353856B2 · Baerveldt · 2013 [cited by applicant]
US 8372437B2 · Daniel · 2013 [cited by applicant]
US 8444588B2 · Yablonski · 2013 [cited by applicant]
US 8444589B2 · Silvestrini · 2013 [cited by applicant]
US 8529492B2 · Clauson et al. · 2013 [cited by applicant]
US 8535333B2 · de Juan, Jr. et al. · 2013 [cited by applicant]
US 8617139B2 · Silvestrini et al. · 2013 [cited by applicant]
US 8672870B2 · Silvestrini et al. · 2014 [cited by applicant]
US 8721656B2 · De Juan, Jr. et al. · 2014 [cited by applicant]
US 8728021B2 · Theodore Coroneo · 2014 [cited by applicant]
US 8758289B2 · Theodore Coroneo · 2014 [cited by applicant]
US 8758290B2 · Horvath et al. · 2014 [cited by applicant]
US 8771218B2 · Coroneo · 2014 [cited by applicant]
US 8808219B2 · Bergheim et al. · 2014 [cited by applicant]
US 8852137B2 · Horvath et al. · 2014 [cited by applicant]
US 8932205B2 · Silvestrini et al. · 2015 [cited by applicant]
US 8945038B2 · Yablonski · 2015 [cited by applicant]
US 8961617B2 · Young · 2015 [cited by applicant]
US 8974511B2 · Horvath et al. · 2015 [cited by applicant]
US 9155656B2 · Schaller et al. · 2015 [cited by applicant]
US 9173774B2 · Yaron et al. · 2015 [cited by applicant]
US 9192516B2 · Horvath et al. · 2015 [cited by applicant]
US 9216107B2 · Silvestrini et al. · 2015 [cited by applicant]
US 9351873B2 · Coroneo · 2016 [cited by applicant]
US 9549845B2 · de Juan, Jr. et al. · 2017 [cited by applicant]
US 9554940B2 · Haffner et al. · 2017 [cited by applicant]
US 9554941B2 · Silvestrini et al. · 2017 [cited by applicant]
US 9585789B2 · Silvestrini et al. · 2017 [cited by applicant]
US 9592151B2 · Rangel-Friedman et al. · 2017 [cited by applicant]
US 9636254B2 · Yu et al. · 2017 [cited by applicant]
US 9788999B2 · Schaller · 2017 [cited by applicant]
US 9877866B2 · Horvath et al. · 2018 [cited by applicant]
US 9962290B2 · Burns et al. · 2018 [cited by applicant]
US 9987472B2 · Tu et al. · 2018 [cited by applicant]
US 10085633B2 · Schaller et al. · 2018 [cited by applicant]
US 10154924B2 · Clauson et al. · 2018 [cited by applicant]
US 10159600B2 · Horvath et al. · 2018 [cited by applicant]
US 10188551B2 · Rangel-Friedman et al. · 2019 [cited by applicant]
US 10285853B2 · Rangel-Friedman et al. · 2019 [cited by applicant]
US 10406030B2 · Badawi et al. · 2019 [cited by applicant]
US 10617558B2 · Schieber et al. · 2020 [cited by applicant]
US 10888460B2 · Sorensen et al. · 2021 [cited by applicant]
US 10905591B1 · Ianchulev · 2021 [cited by applicant]
US 10940087B2 · Thorne et al. · 2021 [cited by applicant]
US 11376040B2 · Kalina, Jr. et al. · 2022 [cited by applicant]
US 11426307B2 · Jacob · 2022 [cited by applicant]
US 11517476B2 · Pinchuk · 2022 [cited by applicant]
US 20020133168A1 · Smedley et al. · 2002 [cited by applicant]
US 20020193886A1 · Claeson et al. · 2002 [cited by applicant]
US 20030139809A1 · Worst et al. · 2003 [cited by applicant]
US 20040167623A1 · Peyman · 2004 [cited by applicant]
US 20040254520A1 · Porteous et al. · 2004 [cited by applicant]
US 20070179455A1 · Geliebter et al. · 2007 [cited by applicant]
US 20070219564A1 · Rue et al. · 2007 [cited by applicant]
US 20080208176A1 · Loh · 2008 [cited by applicant]
US 20080221501A1 · Cote et al. · 2008 [cited by applicant]
US 20090143712A1 · Tu et al. · 2009 [cited by applicant]
US 20100125237A1 · Schocket · 2010 [cited by applicant]
US 20120035743A1 · Young et al. · 2012 [cited by applicant]
US 20140236066A1 · Horvath et al. · 2014 [cited by applicant]
US 20140379015A1 · Sorensen et al. · 2014 [cited by applicant]
US 20150065940A1 · Rangel-Friedman et al. · 2015 [cited by applicant]
US 20150238687A1 · Novakovic et al. · 2015 [cited by applicant]
US 20170095369A1 · Andino et al. · 2017 [cited by applicant]
US 20170258727A1 · Tseng et al. · 2017 [cited by applicant]
US 20180036173A1 · Olson et al. · 2018 [cited by applicant]
US 20190038399A1 · Muller · 2019 [cited by applicant]
US 20190336335A1 · de Juan, Jr. et al. · 2019 [cited by applicant]
US 20200390601A1 · Ianchulev · 2020 [cited by applicant]
US 20210022919A1 · Ianchulev · 2021 [cited by applicant]
US 20210361484A1 · Ianchulev · 2021 [cited by applicant]
US 20220001085A1 · Shi et al. · 2022 [cited by applicant]
US 20220378612A1 · Badawi et al. · 2022 [cited by applicant]
US 20220395397A1 · Chu · 2022 [cited by applicant]
US 20230000680A1 · Ianchulev et al. · 2023 [cited by applicant]
US 20230082713A1 · Ianchulev et al. · 2023 [cited by applicant]
US 20230101775A1 · Detry et al. · 2023 [cited by applicant]
US 20230248569A1 · Vandiest et al. · 2023 [cited by applicant]
US 20230255807A1 · Detry et al. · 2023 [cited by applicant]
US 20250169989A1 · Robson et al. · 2025 [cited by applicant]
CN 86102079A · 1986 [cited by applicant]
CN 2044479U · 1989 [cited by applicant]
CN 101099695A · 2008 [cited by applicant]
CN 102431830A · 2012 [cited by applicant]
CN 102481404A · 2012 [cited by applicant]
CN 104540472A · 2015 [cited by applicant]
CN 105236005A · 2016 [cited by applicant]
CN 105434103A · 2016 [cited by applicant]
CN 107847243A · 2018 [cited by applicant]
CN 109561987A · 2019 [cited by applicant]
EP 1268139B1 · 2004 [cited by applicant]
GB 2551102A · 2017 [cited by applicant]
JP 2013059677A · 2013 [cited by applicant]
JP 2019500130A · 2019 [cited by applicant]
KR 102114787B1 · 2020 [cited by applicant]
WO WO2014089548A1 · 2014 [cited by applicant]
WO WO2017108498A1 · 2017 [cited by applicant]
“Preloaded Dsaek Tissue” Product sheet, Eversight Services, revised Sep. 23, 2019, 1 page. https://www.eversightvision.org/wp-content/uploads/2019/10/Preloaded_DSAEK_23Sept19.pdf (last accessed Nov. 11, 2019). [cited by applicant]
Einmahl et al. (2002). “Evaluation of a novel biomaterial in the suprachoroidal space of the rabbit eye” Invest Ophthalmol Vis Sci. 43:1533-1539. [cited by applicant]
Karlen et al. (Jan. 1999). “Deep sclerectomy with collagen implant: medium term results” Br. J. Ophthalmol, 83(1):6-11. [cited by applicant]
Krejcí L. (1974). “Microdrainage of anterior chamber of eye glaucoma operation using hydron capillary drain.” Acta Univ Carol Med Monogr.; (61):1-90. [cited by applicant]
Larrañeta, E. et al. (2018). “Synthesis and characterization of hyaluronic acid hydrogels crosslinked using a solvent-free process for potential biomedical applications.” Carbohydrate Polymers, 181, 1194-1205. https://d… [cited by applicant]
Murri, M. S. et al. (2018). “Amniotic membrane extract and eye drops: a review of literature and clinical application.” Clinical Ophthalmology (Auckland, N.Z.), 12, 1105-1112. [cited by applicant]
Nesterov, AP et al. (1978). “Implantation of a scleral strip into the supraciliary space and cyclodialysis in glaucoma.” Acta Ophthalmol (Copenh) 56(5):697-704. [cited by applicant]
Nesterov, AP et al. (1979). “Surgical stimulation of the uveoscleral outflow. Experimental studies on enucleated human eyes” Acta Opthalmol (Copenh) June; 57(3):409-17. [cited by applicant]
Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use. Guidance for Industry and Food and Drug Administration Staff. (Jul. 2020). 28 pages. A… [cited by applicant]
Schepens, C.L. et al. (1991). “Scleral Implants: An Historical Perspective.” Ophthalmol 35:447-453. [cited by applicant]
Sun S.Y. et al. (2008). “Therapeutic experience of avoiding faulty formation of anterior chamber after glaucoma operation.” International Journal of Ophthalmology, 8(4); 838-840. [English abstract]. [cited by applicant]
Yeu, E. et al. (2019). “Safety and efficacy of amniotic cytokine extract in the treatment of dry eye disease.” Clinical Ophthalmology, 13, 887-894. [cited by applicant]
Zhao, C. et al. (2004). “Clinical observation of different implants in non-penetrating trabecular surgery,” Journal of Clinical Ophthalmology, 04 2004-08-05; 356-358. [English abstract]. [cited by applicant]